SCHEMBL6176587

SCHEMBL6176587

CCOC(=O)c1ccc(F)nc1NC(=O)C(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.46
ALDH1A1 P00352 4/20 0.46
HPGD P15428 4/20 0.46
HTT P42858 5/20 0.44
NPSR1 Q6W5P4 4/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
RAB9A P51151 3/20 0.44
NPC1 O15118 3/20 0.44
MAPT P10636 3/20 0.44
LMNA P02545 3/20 0.44
GAA P10253 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C19 P33261 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.42
TRPM8 Q7Z2W7 1/20 0.41
TSHR P16473 2/20 0.41
TP53 P04637 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
PDK1 Q15118 1/20 0.40
PDK2 Q15119 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11176088 0.82 MAPT (0.46) KDM4EALDH1A1HPGDHTTNPSR1
SCHEMBL7397465 0.80 L3MBTL1 (0.42) KDM4EALDH1A1NPSR1SMN1; SMN2RAB9A
SCHEMBL6177446 0.79 KDM4E (0.47) KDM4EALDH1A1HPGDHTTNPSR1
SCHEMBL496670 0.75 TSHR (0.52) KDM4EALDH1A1HPGDHTTNPSR1
SCHEMBL6178700 0.74 ALDH1A1 (0.46) KDM4EALDH1A1HPGDHTTNPSR1
SCHEMBL495713 0.73 NR2F2 (0.53) KDM4EALDH1A1NPSR1RAB9ANPC1
SCHEMBL6181328 0.73 ALDH1A1 (0.42) KDM4EALDH1A1HPGDHTTNPSR1
SCHEMBL11181602 0.73 NPC1 (0.51) KDM4EALDH1A1HPGDSMN1; SMN2RAB9A
SCHEMBL6175832 0.71 KDM4E (0.45) KDM4EALDH1A1HPGDHTTNPSR1
SCHEMBL5749751 0.71 KDM4E (0.51) KDM4EALDH1A1SMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1440071-B1 IMIDAZOPYRIDINE COMPOUNDS AS 5-HT 4? RECEPTOR MODULATORS PFIZER (US) 2005-10-26 EP disclosed
EP-1440071-A1 IMIDAZOPYRIDINE COMPOUNDS AS 5-HT 4? RECEPTOR MODULATORS Pfizer Japan Inc. (JP) 2004-07-28 EP disclosed
US-20040034226-A1 Imidazopyridine compounds as 5-HT4 receptor modulators UCHIDA CHIKARA (JP) 2004-02-19 US disclosed
US-6624162-B2 5-HT4 receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, Functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. PFIZER INC. 2003-09-23 US disclosed
US-20030092699-A1 Imidazopyridine compounds as 5-HT4 receptor modulators PFIZER INC. 2003-05-15 US disclosed
WO-2003035649-A1 IMIDAZOPYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS PFIZER JAPAN INC. (JP) 2003-05-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092699-A1 Imidazopyridine compounds as 5-HT4 receptor modulators HTR4, HRH4, HRH2 KDM4E 2141/4885ALDH1A1 2581/4885HPGD 1413/4885
US-20040034226-A1 Imidazopyridine compounds as 5-HT4 receptor modulators HRH4, HTR4, HRH2 KDM4E 1796/4885ALDH1A1 2238/4885HPGD 1468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.